Literature DB >> 12531797

Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells.

Jin Xie1, Ying Wang, Muta E Freeman, Bart Barlogie, Qing Yi.   

Abstract

Two common features in human immunodeficiency virus infection and acquired immunodeficiency syndrome, rheumatoid arthritis, and hematologic malignancies including multiple myeloma are elevated serum levels of beta(2)-microglobulin (beta(2)M) and activation or inhibition of the immune system. We hypothesized that beta(2)M at high concentrations may have a negative impact on the immune system. In this study, we examined the effects of beta(2)M on monocyte-derived dendritic cells (MoDCs). The addition of beta(2)M (more than 10 microg/mL) to the cultures reduced cell yield, inhibited the up-regulation of surface expression of human histocompatibility leukocyte antigen (HLA)-ABC, CD1a, and CD80, diminished their ability to activate T cells, and compromised generation of the type-1 T-cell response induced in allogeneic mixed-lymphocyte reaction. Compared with control MoDCs, beta(2)M-treated cells produced more interleukin-6 (IL-6), IL-8, and IL-10. beta(2)M-treated cells expressed significantly fewer surface CD83, HLA-ABC, costimulatory molecules, and adhesion molecules and were less potent at stimulating allospecific T cells after an additional 48-hour culture in the presence of tumor necrosis factor-alpha and IL-1beta. During cell culture, beta(2)M down-regulated the expression of phosphorylated mitogen-activated protein (MAP) kinases, extracellular signal-related kinase (ERK), and mitogen-induced extracellular kinase (MEK), inhibited nuclear factor-kappaB (NF-kappaB), and activated signal transducer and activator of transcription-3 (STAT3) in treated cells, all of which are involved in cell differentiation and proliferation. Thus, our study demonstrates that beta(2)M at high concentrations retards the generation of MoDCs, which may involve down-regulation of major histocompatibility complex class I molecules, inactivation of Raf/MEK/ERK cascade and NF-kappaB, and activation of STAT3, and it merits further study to elucidate the underlying mechanisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531797     DOI: 10.1182/blood-2002-11-3368

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Dysfunctional T regulatory cells in multiple myeloma.

Authors:  Rao H Prabhala; Paola Neri; Jooeun E Bae; Pierfrancesco Tassone; Masood A Shammas; Charles K Allam; John F Daley; Dharminder Chauhan; Elizabeth Blanchard; Hemant S Thatte; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives.

Authors:  Jing Yang; Qing Yi
Journal:  Am J Blood Res       Date:  2011-06-15

3.  Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma.

Authors:  Siqing Wang; Jing Yang; Jianfei Qian; Michele Wezeman; Larry W Kwak; Qing Yi
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

4.  In vivo effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1-seropositive mothers.

Authors:  Diana B Schramm; Louise Kuhn; Glenda E Gray; Caroline T Tiemessen
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

5.  Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.

Authors:  Philip A Thompson; Francesco Stingo; Michael J Keating; William G Wierda; Susan M O'Brien; Zeev Estrov; Celina Ledesma; Katayoun Rezvani; Muzaffar Qazilbash; Nina Shah; Simrit Parmar; Uday Popat; Paolo Anderlini; Nieto Yago; Stefan O Ciurea; Partow Kebriaei; Richard Champlin; Elizabeth J Shpall; Chitra M Hosing
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

Review 6.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

7.  Proteomic landscape of bronchoalveolar lavage fluid in human immunodeficiency virus infection.

Authors:  Elizabeth V Nguyen; Sina A Gharib; Kristina Crothers; Yu-Hua Chow; David R Park; David R Goodlett; Lynn M Schnapp
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-08       Impact factor: 5.464

8.  Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation.

Authors:  Urban Svajger; Natasa Obermajer; Matjaz Jeras
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397

9.  Linking mechanistic and behavioral responses to sublethal esfenvalerate exposure in the endangered delta smelt; Hypomesus transpacificus (Fam. Osmeridae).

Authors:  Richard E Connon; Juergen Geist; Janice Pfeiff; Alexander V Loguinov; Leandro S D'Abronzo; Henri Wintz; Christopher D Vulpe; Inge Werner
Journal:  BMC Genomics       Date:  2009-12-15       Impact factor: 3.969

Review 10.  Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors.

Authors:  Eric D Brooks; Jonathan E Schoenhals; Chad Tang; Goran Micevic; Daniel R Gomez; Joe Y Chang; James W Welsh
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.